# Rituximab as Second Line Treatment for ITP

> **NCT00344149** · PHASE3 · COMPLETED · sponsor: **Ostfold Hospital Trust** · enrollment: 112 (actual)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Rituximab (Mabthera)

## Key facts

- **NCT ID:** NCT00344149
- **Lead sponsor:** Ostfold Hospital Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2014-03-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00344149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00344149, "Rituximab as Second Line Treatment for ITP". Retrieved via AI Analytics 2026-06-19 from https://api.ai-analytics.org/clinical/NCT00344149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*